Think Research system to support healthcare training | 2023-12-08 | Investing News
- Think Research’s (TSXV:THNK) learning management system was chosen by a global pharma company as a bolt-on white-label education platform
- The three-year SaaS agreement provides clinical trial site onboarding and training to clinical research associates
- This re-occurring contract aims to support continually evolving physician and pharmacist online education needs
- Think Research Corp. last traded at $0.19 per share
Think Research’s (TSXV:THNK) learning management system was chosen by a global pharma company as a bolt-on white-label education platform.
The three-year software-as-a-service (SaaS) agreement provides clinical trial site onboarding and training to clinical research associates. This re-occurring contract aims to support continually evolving physician and pharmacist online education needs.
“Our learning management system continues to gain market momentum with a pharmaceutical client leveraging our technology to deliver essential education and training to clinicians who administer its solutions within healthcare delivery systems,” Sachin Aggarwal, chief executive officer of Think Research said in a news release. “Our data and software division continues to drive essential value for clinicians and healthcare delivery systems globally.”
In other company news, MDBriefCase, a Think Research subsidiary, and global provider of accredited online continuing medical education, is leveraging expertise in oncology to expand education and training partnerships in the field. This is set to include new partnerships with the Canadian Association of Radiation Oncology and Women in Cancer/All in Cancer.
MDBriefCase is also extending its education and training expertise into new specialty areas, expanding into the field of neurology through a new partnership with the Canadian League Against Epilepsy (CLAE). As academic partners, MDBriefCase and CLAE are co-developing a series of educational modules addressing current challenges facing clinicians in the treatment and management of epilepsy, slated for launch in 2024.
Think Research Corp. offers digital health software solutions. It is a provider of cloud-based data, knowledge and software solutions primarily delivered as a SaaS to healthcare delivery systems and the practitioners that they support.
Think Research Corp. last traded at $0.19 per share.
Join the discussion: Find out what everybody’s saying about this stock on the Think Research Corp. Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
link